secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001193125-25-327828
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin ends development of oral AATD liver disease candidate BMN 349
----------------------------------------------------------------------

- Discontinued BMN 349, an oral therapeutic for alpha-1 antitrypsin deficiency (AATD)-associated liver disease.
- Decision announced on December 19, 2025; no reason for discontinuation disclosed.
- No financial impact or pipeline replacement details provided in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312525327828/0001193125-25-327828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312525327828/d45090d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-327828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer